Melissa Shaughnessy

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Joseph J. Eron, Benjamin Young, David A. Cooper et al. · The Lancet · 2010 · 314 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 300 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Mark Sulkowski, Christophe Hézode, Jan Gerstoft et al. · The Lancet · 2014 · 280 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study

Stuart Black, Irene Pak, Paul Ingravallo et al. · Journal of Hepatology · 2015 · 33 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17